Rhythm Pharmaceutical Shares Are Trading Higher After the Company Announced FDA Acceptance for Priority Review of Supplemental NDA for IMCIVREE.
Rhythm Pharmaceutical Shares Are Trading Higher After the Company Announced FDA Acceptance for Priority Review of Supplemental NDA for IMCIVREE.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.